Search research articles
Contact Us
Filters
Showing results (121-130 of 464) with videos related to
Page
of 47
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 2, 2018
Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases
Brian G Feagan, Karen Lasch, Trevor Lissoos, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 19, 2016
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists
Brian G Feagan, David T Rubin, Silvio Danese, et al.
Gut
|
April 26, 2014
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results
Tim Wyant, Tim Leach, Serap Sankoh, et al.
The New England Journal of Medicine
|
July 20, 2007
Certolizumab pegol for the treatment of Crohn's disease
William J Sandborn, Brian G Feagan, Simeon Stoinov, et al.
The American Journal of Gastroenterology
|
April 30, 2019
Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials
Siddharth Singh, James Proudfoot, Parambir S Dulai, et al.
Digestive Diseases and Sciences
|
July 12, 2018
Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy
Jonathan Athayde, Sarah C Davies, Claire E Parker, et al.
Inflammatory Bowel Diseases
|
October 13, 2025
How Should an IBD Prevention Trial Be Designed?
Rogier L Goetgebuer, Ryan C Ungaro, Brian G Feagan, et al.
The American Journal of Gastroenterology
|
July 4, 2014
Comment on 'anti-adhesion therapies and the rule of 3 for rare events'
Brian G Feagan, Jean-Frederic Colombel, Stephen B Hanauer, et al.
Inflammatory Bowel Diseases
|
February 22, 2019
Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews
James E East, Ray K Boyapati, Joana Torres, et al.
Journal of Crohn'S & Colitis
|
May 17, 2024
Serum Extracellular Matrix Molecules and Their Fragments as Biomarkers of Inflammation and Fibrosis in Inflammatory Bowel Diseases: A Systematic Review
Anja Poulsen, Pernille Dige Ovesen, Cathy Lu, et al.
Page
of 47
Search research articles
Search
Showing results (121-130 of 464) with videos related to
Sort By:
Page
of 47
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 2, 2018
Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases
Brian G Feagan, Karen Lasch, Trevor Lissoos, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 19, 2016
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists
Brian G Feagan, David T Rubin, Silvio Danese, et al.
Gut
|
April 26, 2014
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results
Tim Wyant, Tim Leach, Serap Sankoh, et al.
The New England Journal of Medicine
|
July 20, 2007
Certolizumab pegol for the treatment of Crohn's disease
William J Sandborn, Brian G Feagan, Simeon Stoinov, et al.
The American Journal of Gastroenterology
|
April 30, 2019
Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials
Siddharth Singh, James Proudfoot, Parambir S Dulai, et al.
Digestive Diseases and Sciences
|
July 12, 2018
Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy
Jonathan Athayde, Sarah C Davies, Claire E Parker, et al.
Inflammatory Bowel Diseases
|
October 13, 2025
How Should an IBD Prevention Trial Be Designed?
Rogier L Goetgebuer, Ryan C Ungaro, Brian G Feagan, et al.
The American Journal of Gastroenterology
|
July 4, 2014
Comment on 'anti-adhesion therapies and the rule of 3 for rare events'
Brian G Feagan, Jean-Frederic Colombel, Stephen B Hanauer, et al.
Inflammatory Bowel Diseases
|
February 22, 2019
Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews
James E East, Ray K Boyapati, Joana Torres, et al.
Journal of Crohn'S & Colitis
|
May 17, 2024
Serum Extracellular Matrix Molecules and Their Fragments as Biomarkers of Inflammation and Fibrosis in Inflammatory Bowel Diseases: A Systematic Review
Anja Poulsen, Pernille Dige Ovesen, Cathy Lu, et al.
Page
of 47